BACKGROUND: Thrombosis is the most common complication of hemodialysis access. Few reports are available concerning the use of recombinant tissue plasminogen activator (rt-PA) to declot an arterio-venous (A-V) access. This report describes the use of rt-PA for this purpose in 17 A-V accesses. METHODS: The rt-PV was infused manually using a small catheter directly into the A-V access in 10-mg doses at 1-2 hour intervals, to a maximum dose of 40 mg. The procedure was followed by angiography, through the same catheter. RESULTS: One fistula could not be cannulated, and in three the lysis of the clot failed. The other 13 cases (3 fistulas, and 10 grafts 81%) had successful lysis with return of bruit and thrill. Most patients had dialysis the next day using the declotted A-V access. Angiogram detected stenosis in six patients and surgical revision was done 1-8 days after the treatment. In the other seven patients no organic lesions were found, and six of them have a functioning A-V access 50-395 days after the lysis. Only 10-20 mg of rt-Pa was needed in 60% of the cases. No major complication occurred; minor local bleeding was noted in five patients (5/16, 31%). CONCLUSION: rt-PA can be considered safe, effective, and fast for declotting thrombosed arteriovenous fistulas.
BACKGROUND:Thrombosis is the most common complication of hemodialysis access. Few reports are available concerning the use of recombinant tissue plasminogen activator (rt-PA) to declot an arterio-venous (A-V) access. This report describes the use of rt-PA for this purpose in 17 A-V accesses. METHODS: The rt-PV was infused manually using a small catheter directly into the A-V access in 10-mg doses at 1-2 hour intervals, to a maximum dose of 40 mg. The procedure was followed by angiography, through the same catheter. RESULTS: One fistula could not be cannulated, and in three the lysis of the clot failed. The other 13 cases (3 fistulas, and 10 grafts 81%) had successful lysis with return of bruit and thrill. Most patients had dialysis the next day using the declotted A-V access. Angiogram detected stenosis in six patients and surgical revision was done 1-8 days after the treatment. In the other seven patients no organic lesions were found, and six of them have a functioning A-V access 50-395 days after the lysis. Only 10-20 mg of rt-Pa was needed in 60% of the cases. No major complication occurred; minor local bleeding was noted in five patients (5/16, 31%). CONCLUSION: rt-PA can be considered safe, effective, and fast for declotting thrombosed arteriovenous fistulas.
Authors: Richard Chang; McDonald K Horne; Thomas H Shawker; Anthony W Kam; Enn Alexandria Chen; Galen O Joe; Willie L Ching; Edie Mao; David A Wyrick; Jay N Lozier Journal: J Vasc Interv Radiol Date: 2011-06-12 Impact factor: 3.464